AU Patent

AU2013301606A1 — Genetic markers for predicting responsiveness to FGF-18 compound

Assigned to Merck Patent GmbH · Expires 2015-03-05 · 11y expired

What this patent protects

This application is directed to the use of biomarkers for predicting the sensitivity to treatment with an FGF-18 compound in a patient having a cartilage disorder, such as osteoarthritis, cartilage injury, fractures affecting joint cartilage or surgical procedures with impact on …

USPTO Abstract

This application is directed to the use of biomarkers for predicting the sensitivity to treatment with an FGF-18 compound in a patient having a cartilage disorder, such as osteoarthritis, cartilage injury, fractures affecting joint cartilage or surgical procedures with impact on joint cartilage (e.g. Microfracture), in order to reduce the risk of adverse events and increase the overall benefit after therapy.

Drugs covered by this patent

Patent Metadata

Patent number
AU2013301606A1
Jurisdiction
AU
Classification
—
Expires
2015-03-05
Drug substance claim
No
Drug product claim
No
Assignee
Merck Patent GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.